Novavax, Fujifilm lock up supply for late-stage COVID-19 vaccine trial

Novavax, Fujifilm lock up supply for late-stage COVID-19 vaccine trial

Source: 
Fierce Pharma
snippet: 

Maryland biotech Novavax scored a big leg up in its hunt for a COVID-19 vaccine with a major infusion from the Trump administration this month. Now, Novavax is using some of those funds to help supply doses of its shot for a pivotal late-stage trial down the road.

Fujifilm Diosynth Biotechnologies will churn out clinical supply for a phase 3 trial of Novavax's COVID-19 vaccine candidate expected to begin in the fall, according to a manufacturing pact signed Thursday.